Montreal, June 10, 2009 - Clinicians from the Centre hospitalier de l'Université de Montréal (CHUM) have perfected an operation, which was previously considered too dangerous, to control refractory ...

Since 1975, the ADD program has been testing and identifying antiseizure drugs for the nearly one-third of people with epilepsy that is refractory to current medications. The University of Utah ...

LONDON--(BUSINESS WIRE)--EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy, today announced it has raised a ...

A team of researchers from the Universitat Politècnica de València (UPV) has participated in the development of Epileptika. This application aims to help the treatment of refractory epilepsy in people ...

Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...

Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory ...

Suggested Citation: "Appendix C: Data on Specialized Epilepsy Centers: Report to the Institute of Medicine's Committee on the Public Health Dimensions of the Epilepsies." Institute of Medicine. 2012.

Epilepsy affects one in every 100 people—1 million in Japan and 50 million worldwide. It is the third most common brain disease after stroke and dementia. In Japan, its incidence and prevalence have ...

EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing ...